These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 15482377

  • 1. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
    Umar A, Boisseau M, Yusup A, Upur H, Bégaud B, Moore N.
    Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377
    [Abstract] [Full Text] [Related]

  • 2. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 3. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 4. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 5. COX-1 and COX-2 inhibitors.
    Hawkey CJ.
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
    [Abstract] [Full Text] [Related]

  • 6. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 7. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 8. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 9. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May 27; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

  • 10. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 11. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J.
    Pharmacoepidemiol Drug Saf; 2003 May 04; 12(1):67-70. PubMed ID: 12616850
    [No Abstract] [Full Text] [Related]

  • 12. [Analgesic in osteoporosis. Why so conservative with dosage?].
    Pfeifer M.
    MMW Fortschr Med; 2002 Sep 05; 144(35-36):9. PubMed ID: 12380349
    [No Abstract] [Full Text] [Related]

  • 13. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G, Bilò MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, Dama AR.
    Eur Ann Allergy Clin Immunol; 2004 Jun 05; 36(6):215-8. PubMed ID: 15329003
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Safety of specific cyclo-oxygenase 2 inhibitors].
    Lems WF, van de Laar MA, Bijlsma JW.
    Ned Tijdschr Geneeskd; 2001 Jun 02; 145(22):1044-7. PubMed ID: 11414163
    [Abstract] [Full Text] [Related]

  • 18. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
    Wallace JL, Zamuner SR, McKnight W, Dicay M, Mencarelli A, del Soldato P, Fiorucci S.
    Am J Physiol Gastrointest Liver Physiol; 2004 Jan 02; 286(1):G76-81. PubMed ID: 14665439
    [Abstract] [Full Text] [Related]

  • 19. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA.
    J Clin Pharmacol; 2000 Dec 02; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [Abstract] [Full Text] [Related]

  • 20. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
    Schwartz JI, Chan CC, Mukhopadhyay S, McBride KJ, Jones TM, Adcock S, Moritz C, Hedges J, Grasing K, Dobratz D, Cohen RA, Davidson MH, Bachmann KA, Gertz BJ.
    Clin Pharmacol Ther; 1999 Jun 02; 65(6):653-60. PubMed ID: 10391671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.